Compare AstraZeneca plc (AZN) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.05. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AZN | TLT | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $92.06 |
52-Week Low | $147.06 | $82.05 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
TLT (iShares 20+ Year Treasury Bond ETF) trades at $82.11, showing minimal daily movement with a 0.08% gain. The technical outlook remains bearish with moving averages signaling strong selling pressure, while oscillators indicate neutral momentum. Recent news highlights pressure from rising Treasury yields and concerns about US debt levels approaching $40 trillion, with institutional activity showing Ferguson Shapiro LLC acquiring 37,900 shares in the latest quarter.
The ETF faces headwinds from rising long-term yields and inflation concerns, though recent dividend payments provide income support. Key risks include Federal Reserve policy uncertainty and escalating geopolitical tensions affecting bond markets. Investors should monitor inflation data and Treasury yield movements for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
